Correction:Crit Care (2023) 27:359 https://doi.org/10.1186/s13054-023-04631-2
Following publication of the original article [1], the authors identified an error in Table 1. The results were inverted between for variable No decrease in consciousness Day 1–Day 2. The correct table is given hereafter.
Table 1
Baseline characteristics and mortality rate for patients with non-ventilator-associated ICU-acquired pneumonia admitted to an ICU for severe acute exacerbation of chronic obstructive pulmonary disease
No NV-ICU-AP (n = 802) | NV-ICU-AP (n = 42) | p value | |
|---|---|---|---|
Median [Q1; Q3] or n (percentage) | Median [Q1; Q3] or n (percentage) | ||
Baseline characteristics | |||
Age (years) | 70.7 [62.0; 78.1] | 72.3 [67.6; 76.9] | 0.33 |
Male sex, n (%) | 499 (62.2) | 31 (73.8) | 0.13 |
BMI (kg/m2) | 24.9 [20.8; 30.3] | 23.9 [21.2; 30.1] | 0.74 |
SAPS II score | 34.0 [26.0; 42.0] | 38.0 [30.0; 45.0] | 0.05 |
Maximum SOFA Day 1- Day 2 | 4.0 [3.0; 6.0] | 5.0 [3.0; 6.0] | 0.06 |
Hospitalisation before ICU admission (yes), n (%) | 264 (32.9) | 20 (47.6) | 0.05 |
Immunodeficiency (yes), n (%) | 74 (9.2) | 6 (14.3) | 0.28 |
No decrease in consciousness Day 1- Day 2 (Glasgow Coma Scale = 15) | 490 (61.1) | 14 (33.1) | < 0.01 |
MDR bacterial colonization, (yes), n (%) | 47 (5.9) | 3 (7.1) | 0.73 |
COPD severity | |||
Very Severe COPD, n (%) | 173 (21.6) | 1 (2.4) | < 0.01 |
Trigger of the acute exacerbation of COPD | |||
Respiratory infection, n (%) | 524 (65.3) | 29 (69.0) | 0.74 |
Non-infectious respiratory causes, n (%) | 165 (20.6) | 8 (19.0) | |
Cardiac and thromboembolic events, n (%) | 63 (7.9) | 4 (9.5) | |
Others, n (%) | 50 (6.2) | 1 (2.4) | |
Therapeutic limitation | |||
Limitation of therapeutic effort at admission to ICU, (yes) n (%) | 63 (7.9) | 3 (7.1) | 0.87 |
Corticosteroid therapy | |||
Use of corticosteroids therapy at admission, (yes) n (%) | 302 (37.7) | 12 (28.6) | 0.24 |
Antibiotic therapy | |||
Use of antibiotic therapy at admission, (yes) n (%) | 561 (70.0) | 25 (59.5) | 0.15 |
Gastroprotective agents | |||
Use of gastroprotective agents at admission, (yes) n (%) | 411 (51.2) | 22 (52.4) | 0.89 |
Enteral nutrition | |||
Use of enteral nutrition at admission, (yes) n (%) | 99 (12.3) | 10 (23.8) | 0.03 |
Lengths of stay | |||
ICU Length of stay (days) | 6.0 [5.0; 10.0] | 24.5 [14.0; 37.0] | < 0.01 |
Hospital Length of stay (days) | 18.0 [12.0; 30.0] | 37.0 [22.0; 59.0] | < 0.01 |
Mortality | |||
ICU Mortality rate, n (%) | 73 (9.1) | 16 (38.1) | < 0.01 |
Hospital Mortality rate, n (%) | 123 (15.3) | 18 (42.9) | < 0.01 |
Mortality at Day 28, n (%) | 96 (12.0) | 10 (23.8) | 0.02 |
Non-ventilator-associated ICU-acquired pneumonia | |||
Day of first diagnosis of NV-ICU-AP (days in ICU) | – | 6.0 [4.0; 11.0] | |
Day of first diagnosis of NV-ICU-AP (days in hospital) | – | 7.5 [5.0; 16.0] | |
NV-ICU-AP requiring intubation, (yes) n (%) | – | 32 (76.2) | |
Anzeige
The incorrect Table 1 values are:
In the No NV-ICU-AP population, the number of patients with No decrease in consciousness Day 1–Day 2 (Glasgow Coma Scale = 15) is 312 (38.9%)
In the NV-ICU-AP population, the number of patients with No decrease in consciousness Day 1–Day 2 (Glasgow Coma Scale = 15) is 28 (66.7%)
The correct Table 1 values are:
Anzeige
In the No NV-ICU-AP population, the number of patients with No decrease in consciousness Day 1–Day 2 (Glasgow Coma Scale = 15) is 490 (61.1%)
In the NV-ICU-AP population, the number of patients with No decrease in consciousness Day 1–Day 2 (Glasgow Coma Scale = 15) is 14 (33.1%)
Table 1 has been updated in this correction article and the original article [1] has been corrected.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.